Onivyde, also known as irinotecan liposome, has a complex pharmacokinetic profile due to its liposomal formulation. The half-life of the active chemotherapy drug, irinotecan, is influenced by its encapsulation within liposomes [1].
How long does Onivyde stay in the body?
The systemic exposure to irinotecan from Onivyde is prolonged compared to irinotecan hydrochloride injection. The mean terminal elimination half-life of irinotecan in plasma following Onivyde administration is approximately 35 hours [2]. This extended half-life is a characteristic of liposomal drug delivery, which allows for sustained release of the active agent [1].
What is the active ingredient in Onivyde?
The active ingredient in Onivyde is irinotecan, a topoisomerase I inhibitor [2]. In Onivyde, irinotecan is encapsulated within small, unilamellar liposomes [1]. This formulation is designed to alter the pharmacokinetic properties of irinotecan, potentially leading to improved efficacy and a different safety profile compared to the conventional irinotecan hydrochloride injection [2].
How is Onivyde administered?
Onivyde is administered intravenously [2]. It is typically given as a single dose, with the specific dosage and duration of treatment determined by a healthcare professional based on the patient's condition and response [2].
What are the main side effects of Onivyde?
The most common adverse reactions associated with Onivyde include diarrhea, fatigue, neutropenia, nausea, vomiting, decreased appetite, stomatitis, and abdominal pain [2]. Diarrhea is a significant side effect that requires prompt management [3].
What is the difference between Onivyde and irinotecan hydrochloride?
Onivyde is a liposomal formulation of irinotecan, while irinotecan hydrochloride is the conventional injectable form of the drug [1, 2]. The liposomal encapsulation in Onivyde modifies the way irinotecan is distributed and eliminated in the body, leading to a prolonged half-life and potentially altered efficacy and toxicity profiles compared to irinotecan hydrochloride [1, 2].
What are the approved uses for Onivyde?
Onivyde is approved for the treatment of adult patients with metastatic adenocarcinoma of the pancreas, after disease progression following gemcitabine-based chemotherapy [2].
Where can I find more information about Onivyde's drug patents and exclusivity?
Information regarding drug patents and market exclusivity for Onivyde and its active ingredient, irinotecan, can be found on DrugPatentWatch.com [4].
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.fda.gov/
3. https://www.nejm.org/
4. https://www.drugpatentwatch.com/